Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Inventory (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Inventory for 11 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory fell 21.91% to $8.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.7 million, a 21.91% decrease, with the full-year FY2025 number at $11.4 million, down 5.82% from a year prior.
  • Inventory was $8.7 million for Q4 2025 at Aytu Biopharma, down from $10.1 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $16.6 million in Q4 2021 to a low of $8.7 million in Q4 2025.
  • A 5-year average of $12.7 million and a median of $12.9 million in 2022 define the central range for Inventory.
  • Peak YoY movement for Inventory: soared 151.98% in 2021, then plummeted 33.6% in 2022.
  • Aytu Biopharma's Inventory stood at $16.6 million in 2021, then dropped by 21.79% to $13.0 million in 2022, then rose by 0.39% to $13.0 million in 2023, then decreased by 14.74% to $11.1 million in 2024, then decreased by 21.91% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Inventory are $8.7 million (Q4 2025), $10.1 million (Q3 2025), and $11.4 million (Q2 2025).